Treatment.com AI Inc. (C:TRUE)
Business Focus: Medical Software & Technology Services
Mostly sunny as of May 01, 2024
For the latest outlook, get the company report
Insider Filings
Latest 10 SEDI filings for TRUE within the last 6 months
See all filings within the past 6 months
Read full article
Read full article
See more news stories
See all valuations
See Short Report
Loading...
Company News
May 15, 2024 08:45 ET
Artificial Intelligence Enabled Technologies Transforming Healthcare Industry Creating Multi-Billion Dollar Opportunities
FN Media Group News Commentary - Experts see substantial growth in the global AI Healthcare market over the next several years. A report from Statista said that: “The artificial intelligence (AI) in healthcare market was… forecast that (it) would...
May 15, 2024 08:00 ET
Treatment.com AI and Novus Health Partnership Expands Access to its Global Library of Medicine (GLM)
Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939) (“Treatment”) is pleased to announce it has signed a Collaborative Agreement with Health Care Services International Inc (o/a Novus Health). (“Novus Health”) to explore utilization of...
Valuation Ratios
Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
--
6.65
3.80
Price to Book - most recent quarter
--
3.65
2.44
Price to Cash Flow per share - TTM
--
11.98
10.09
Price to Free Cash Flow per share - TTM
--
17.51
17.38
Short Report
| Date | Number of Shares Shorted | Net Change |
|---|---|---|
| Apr 30, 2024 | 11,592 | -63,672 |
| Apr 15, 2024 | 75,264 | 72,376 |
| Mar 31, 2024 | 2,888 | 2,845 |
Business Summary
| Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
Treatment.com AI Inc., through its wholly owned subsidiary, Treatment.com Inc., is in the business of providing personalized health care information. The Company has developed a personalized healthcare artificial intelligence (AI) engine, the Global Library of Medicine (GLM), which is engaged in providing clinical information and support to all healthcare professionals. The GLM delivers over 92% accuracy on first diagnosis as well as providing recommended tests (physical and lab), x-rays, and billing codes. Its solutions include medical education solution, medical clinic solution and clinical advisor solution. It also focuses on the next generation of healthcare professionals supporting medical and nursing schools, who utilize the GLM to help improve the clinical skills of their students. It is also focused on using AI for utilizing its GLM platform to bring the possibility of health equity and inclusion for disenfranchised communities.
See business summary
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.